Pembrolizumab with Chemotherapy for Patients with Recurrent or Metastatic Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma: A Prospective Phase ll Study
Pembrolizumab plus nab-paclitaxel and platinum shows promising antitumor activity and manageable safety in patients with first-line R/M SNSCC.
Authors
- Yuquan Qian (ORCID: https://orcid.org/0000-0003-2721-700X)
- Le Tang (ORCID: https://orcid.org/0000-0002-5192-3329)
- Haizhen Lu (ORCID: https://orcid.org/0000-0001-7564-794X)
- Changming An (ORCID: https://orcid.org/0000-0002-8353-4547)
- Jiarui Yao (ORCID: https://orcid.org/0000-0002-9835-395X)
- Weihua Li (ORCID: https://orcid.org/0009-0006-2163-3335)
- Ye Zhang (ORCID: https://orcid.org/0000-0002-6052-0708)
- Lin Gui
- Yiming Zhu (ORCID: https://orcid.org/0000-0002-1267-2897)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- National Cancer Center (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-02-24
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-4148
- Citations
- 4
- Primary Topic
- Head and Neck Surgical Oncology
- Type
- article
- Field-Weighted Citation Impact
- 8.03